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Abstract
Oncolytic viruses refer to those that are able to eliminate malignancies by direct targeting and lysis of cancer cells,
leaving non-cancerous tissues unharmed. Several oncolytic viruses including adenovirus strains, canine distemper
virus and vaccinia virus strains have been used for canine cancer therapy in preclinical studies. However, in contrast
to human studies, clinical trials with oncolytic viruses for canine cancer patients have not been reported. An ‘ideal’
virus has yet to be identified. This review is focused on the prospective use of oncolytic viruses in the treatment of
canine tumors - a knowledge that will undoubtedly contribute to the development of oncolytic viral agents for
canine cancer therapy in the future.
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1. Introduction
Cancer is the most common cause of natural death in
dogs and endemic in both developed and developing
countries [1,2]. Incidence of cancer ranges from 1 to 2%
in the canine population and currently accounts for
about half of the deaths in dogs older than 10 years
[1,3]. The major treatment options for canine cancers
include surgery, radiation therapy, chemotherapy,
hyperthermia and photodynamic therapy. As the stan-
dard therapy is usually palliative in canine cancer, there
is an excellent opportunity to evaluate alternative
approaches.
A promising therapeutic approach is the oncolytic vir-
otherapy. Oncolytic viruses selectively infect, replicate
and kill cancer cells, while leaving healthy cells intact.
Evidence that viruses may be useful in the eradication of
cancer has existed since the early twentieth century
[4,5]. These early discoveries have led to the testing of
several viruses against cancers in both pre-clinical and
clinical settings during the 1950s and 1960s [6]. Alice
Moore was the first scientist to test oncolytic
virotherapy in an animal model. Working with Russian
Far East encephalitis virus, complete regression was
achieved in some cases of mouse sarcoma 180 - the first
animal model to demonstrate full regression through
viral oncolysis [7]. However, during the last 15 years
numerous reports have confirmed that intratumorally or
systemically delivered viruses such as Newcastle disease
virus (NDV) [8], reovirus [9], lentivirus [10] herpes sim-
plex virus (HSV) [11], enterovirus [12], Sindbis virus
[13], Semliki Forest virus [14] Seneca Valley virus [15],
adenovirus [16], vaccinia virus [17], myxoma [18] and
raccoonpox virus [19] could display an antitumor activ-
ity in different animal models (for more detailed list of
oncolytic viruses readers are directed to [20-22]). Several
oncolytic virus (OV) platforms (herpes simplex virus,
vaccinia virus, Seneca valley virus and reovirus) are cur-
rently in or entering Phase III human clinical trials. In
addition, in China the oncolytic adenovirus H101 has
been approved in the treatment of human patients with
head and neck cancer since 2005 [23].
However, currently the use of oncolytic virotherapy in
veterinary medicine is far from reality and promising
laboratory results have to be translated into improved
clinical outcomes. This review describes the most com-
mon classes of oncolytic viruses for canine cancer ther-
apy, and focuses on ways in which these viruses may be
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manipulated in order to target, enhance and exploit
their cytolytic properties for treatment of canine cancer.
2. Oncolytic Virotherapy for Canine Cancer
Oncolytic viruses such as various human and canine
adenoviruses, canine distemper virus (CDV) and vacci-
nia virus strains have been preclinically tested for canine
cancer therapy.
Adenoviruses are medium-sized (90-100 nm), none-
nveloped icosohedral viruses containing double-stranded
DNA. They are well characterised for oncolytic therapy
in humans and have the ability to infect a broad range
of cells cross-species [24,25]. These viruses are restricted
to cancer cells at the replication level and hence called
conditionally replicating adenoviruses (CRAds). E1A and
E1B gene regions of wild type adenovirus are deleted,
making virus replication competent in those cells in
which pRb pathway or p53 apoptosis pathway is defec-
tive [26]. Moreover, control mechanisms have been
added to adenoviruses to ensure cancer cell specificity,
and arming the virus with suicide genes has also been
explored to improve therapeutic effects [27]. Adeno-
viruses are also being tested as therapeutic agents for
canine cancers. Human adenovirus 5 has been shown to
productively replicate in canine osteosarcoma and
canine mammary carcinoma cells [28]. Furthermore,
canine adenovirus 2 (CAV-2), transcriptionally targeted
to canine osteosarcoma cells by inserting osteocalcin
promoter, was tested as therapeutic agent for canine
osteosarcoma. As this promoter is active only in osteo-
sarcoma cells and not active in other canine non neo-
plastic cells, CAV-2 with osteocalcin promoter showed
restricted replication in canine osteosarcoma cells [29].
This modified canine adenovirus killed canine osteosar-
coma cells in cell culture and showed therapeutic bene-
fits in xenograft model [30]. Moreover, administration
of CAV-2 to normal dogs showed no major signs of
virus-associated toxicity [29]. Arming an adenoviral vec-
tor has yielded promising results in canine malignant
melanoma cases. Intratumoral injections of this adeno-
viral vector with CD40 ligand (AdCD40L) revealed inhi-
bition of tumor progression and metastasis in two
canine malignant melanoma cases. Also, injections of
AdCD40L were safe and no signs of systemic toxicity
were observed in canine patients throughout the treat-
ment period [31]. Extension of such studies to clinical
trials in the canine population will likely provide better
understanding of the oncolytic properties, safety, and
therapeutic efficiency of adenoviruses.
Canine distemper virus (CDV) is an enveloped virus
with a single stranded RNA genome belonging to the
family paramyxoviridae [32]. It is a morbillivirus and
possesses many common features with human Measles
virus (MV) including its clinical outcomes [33]. Clinical
consequences of CDV and MV include profound
immune suppression and lymphopenia. Interestingly,
regression of Hodgkin’s disease was observed in children
after concurrent MV infection [34,35] which prompted
consideration of the use of attenuated CDV for treat-
ment of canine lymphoma. Moreover, CDV binds to a
cellular receptor, Signalling Lymphocyte Activation
Molecule (SLAM or CD150) [36,37]. Canine lymphoid
cell lines and B and T lymphocytes established from
dogs with lymphoma have been shown to express
CD150 receptors. Attenuated CDV has been tested for
oncolytic property in the lymphoma cells and was able
to infect and induce apoptosis in these cells [33]. It may
therefore be used to treat canine lymphoma patients.
In addition, several preclinical and clinical studies with
vaccinia virus (VACV) helped to determine its oncolytic
property. VACV is a member of the poxvirus family
characterised by double stranded DNA genome [38,39].
It was the first widely used vaccine (in over 200 million
people) resulting in eradication of smallpox worldwide,
and therefore much is known about its safety profile
[40]. Two oncolytic vaccinia virus strains, namely JX-
594 (Jennerex Biotherapeutics, Inc. USA) and GLV-1h68
(Genelux Corporation, USA), have shown promising
preclinical data and are now undergoing clinical trials in
humans [17,41,42]. The JX594 construct is based on a
thymidine kinase (tk) gene-deleted strain derived from
the Wyeth strain and expresses GM-CSF and beta-galac-
tosidase (LacZ) [43]. GLV-1h68 (denominated as GL-
ONC1 when produced under GMP conditions) was
developed on the base of the Lister strain and carries
the gene sequences for a fusion protein of Renilla luci-
ferase and Green Fluorescent Protein (Ruc-GFP), LacZ
and beta-glucuronidase (GusA) [17]. In addition, GLV-
1h68 has been proposed for the treatment of canine
mammary adenoma and carcinoma [44,45]. The effect
of this virus was studied in vitro in the canine mammary
carcinoma cell line MTH52c and canine mammary ade-
noma cell line ZMTH3 and in xenograft models in nude
mice. These studies revealed that GLV-1h68 could effi-
ciently infect, replicate in and destroy canine mammary
carcinoma MTH52c cells and canine mammary ade-
noma ZMTH3 cells in culture. Furthermore, in both
cases, significant inhibition of tumor growth and
damage of tumor tissues was observed after systemic
administration of GLV-1h68 in tumor bearing nude
mice [44,45]. Additionally, the opportunity to localize
GLV-1h68 viruses via optical imaging might be utilized
in metastasis detection [46]. Moreover, the oncolytic
vaccinia virus strain LIVP 1.1.1 efficiently kills canine
soft tissue sarcoma cells (Gentschev I et. al., sub-
mitted). In this very recent study, a systemic adminis-
tration of LIVP 1.1.1 virus, a new variant isolated from
the wild-type LIVP strain (Chen et. al, unpublished
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data), led to significant growth inhibition and regression
of the tumors in a canine sarcoma xenograft mouse
model (Gentschev I et. al submitted). The LIVP 1.1.1
mediated therapy was further shown to be sufficient for
long-term survival of sarcoma bearing mice and resulted
in almost complete tumor regression.
Other poxviruses have also been explored as oncolytic
agents for canine tumors. Pre-clinical studies with
recombinant canary pox viruses (ALVAC) expressing
interleukin 2 have shown the utility of these vectors in
promoting anti-tumor activity [47]. Based upon these
results, the effect of ALVAC was also analyzed clinically
in canine cancer patients. Intratumoral administration of
this recombinant poxvirus in dogs with melanoma
revealed localized distribution of virus into tumor tissue
[48]. Moreover, an ALVAC vaccine against canine dis-
temper virus (RECOMBITEK rDistemper, Merial, USA),
has been approved by the USDA and has been demon-
strated to be safe and effective in preventing disease in
practical field use. However, there are no data regarding
the anti-tumor efficacy of ALVAC in canine patients.
For a more detailed overview, the characteristics of sev-
eral oncolytic viruses are listed in Table 1.
3. Current and Future Challenges of Oncolytic
Viral therapy for Canine Cancers
Despite encouraging progress in the field of oncolytic
viral therapy, several limitations remain in the develop-
ment of an ideal OV including selective targeting of
OVs to tumor tissue, relatively poor virus-spread
throughout solid tumor tissue, inefficient viral replica-
tion in immune-competent hosts and disadvantageous
ratio between anti-viral and anti-tumoral immunity. Sev-
eral strategies to overcome these limitations are cur-
rently being investigated. The major strategies include
the improvement of existing oncolytic vector systems or
using combinations of oncolytic viruses with existing
clinical methods or agents for synergistic and/or additive
anti-tumor responses. Oncolytic virotherapy for canine
cancers is still in its infancy; however, exciting develop-
ments in this pioneering approach are expected. This
novel therapy has limitations which need to be
addressed to improve efficacy, safety and clinical applic-
ability. An overview of some of the problems and solu-
tions is described here.
3.1 Selective targeting of oncolytic virus to tumor tissue
A major caveat for the widespread clinical use of vir-
otherapy in canine cancer is to ensure that viruses do
not harm normal cells. Certain viruses like NDV, reo-
virus, vesicular stomatitis virus (VSV), measles virus and
others have natural tumor tropism [49-52]. However,
better understanding of molecular events of virus-cell
interactions in recent years has allowed for the design of
genetically engineered viruses that target selected mole-
cules or signalling pathways such as p16, p21 p53, IFN
pathway, PTEN, EGFR, VEGFR, STAT3, HSP70, anti-
apoptosis or hypoxia. Adenoviruses and vaccinia viruses
are directed to human cancer cells by taking advantage
of these defective pathways. Adenoviruses are designed
Table 1 Oncolytic viruses for canine cancer therapy
Virus Strains/
ref.
Advantages Disadvantages
Adenovirus CAV-1
[30]
CAV-2
[29]
Infection of both dividing and non dividing cells.
High viral titres in tumor tissue.
Induction of immune response.
Efficient gene transfer.
Pre-existing immunity in canine
population.
Small insert capacity.
Canine
Distemper
Virus
CDV [33] Natural tumor tropism as cellular receptor for entry CD46 is expressed on tumor
cells.
Good safety records as included in vaccine schedule of canines.
Only lymphoma therapy data
Vaccinia
Virus strains
GLV-
1h68
[44,45]
Broad host range.
Attenuated by three insertion cassettes.
Large recombinant gene capacity.
Efficient gene transfer and expression.
No chance for integration of viral genome in to host.
Induction of virus-mediated immune
response
LIVP Attenuated by natural mutation in thymidine kinase (tk) gene.
Safety of virus is well known.
Broad host range.
Replication in host cytoplasm only, no chance for integration of viral genome in
to host.
Insertion of largest DNA fragment (about 25 kBps) for gene therapy.
Only tested for canine soft tissue
sarcoma.
Canary Pox
virus
ALVAC
[47]
Producing an immune response without any adjuvant.
Approved by the USDA as a vaccine against canine distemper virus (RECOMBITEK
canine distemper)
Protection against canine distemper
virus only
Abbreviations: CAV-1: Canine adenovirus - 1, CAV-2: Canine adenovirus - 2, CDV: Canine distemper virus, LIVP: Lister strain of Vaccinia virus, ALVAC: Recombinant
canarypox virus, GLV-1h68: Recombinant Vaccinia virus by Genelux Corporation USA.
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to target human cancer cells mutated for tumor sup-
pressor protein p53. The viral protein encoded by the
E1 region of wild type adenovirus binds and inactivates
p53, allowing replication of virus in normal cells [53].
Because tumor cells lacking functional p53 gene are
unable to suppress replication of mutant adenoviruses,
E1 gene-deleted adenoviruses have diminished ability to
replicate in normal cell and preserved replication in
neoplastic cells [26]. Canine p53 family proteins have
biological activities similar to their human counterparts
[54], with more than 85% gene sequence similarity. In
addition, p53 mutations in canine tumors are located
within the exons similar to those reported in human
genes [55], and mutations in conserved domains of p53
appear to play a significant role in mammary carcino-
genesis in both humans and dogs [56]. Like in human
tumors, the p53 gene is mutated in several canine can-
cers, including osteosarcoma [57], mammary tumors
[58] and gastric carcinoma [59]. All these points suggest
that canine and human p53 protein has similar biologi-
cal functions which can be helpful in designing better
therapeutic modalities against canine cancer. Thus,
oncolytic viruses, especially adenovirus, can specifically
be targeted to canine cancer cells by taking advantage of
the defective p53 pathway. In another example, VACV
mutants with deletions in the thymidine kinase gene (tk)
and/or vaccinia growth factor gene (VGF) are well
advanced in pre-clinical and clinical studies for human
cancers [60,61]. These mutants grow selectively in can-
cer cells with high levels of cellular thymidine kinase
(TK), and constitutively activated EGFR/Ras pathway
signalling complements the loss of the viral gene pro-
ducts [62]. Moreover, tumor cells release the TK
enzyme to the circulation, probably due to disruption of
dead or dying tumor cells [63]. Increased serum TK
activity was observed in various canine malignancies like
lymphoma [63,64], leukemia [65] and hemangiosarcoma
[66], suggesting a possible target for directing Vaccinia
virus to tumor tissue. In addition, higher expression of
EGFR in mammary [67], glioma [68], hepatocellular car-
cinoma [69] and malignant epithelial nasal tumors [70]
of canine origin closely parallels that of human tumors
of the same type and histologic grade. High levels of
EGFR and TK in various canine cancers could be basis
of enhancing replication of Vaccinia virus in canine can-
cer cells.
To further enhance the tropism of vaccinia virus to
human cancer cells, Kirn and colleagues deleted the
B18R gene, which encodes a protein that neutralizes
type I interferons (IFNs), producing a highly tumor-spe-
cific oncolytic vaccinia virus [71]. IFNs are a group of
secreted cytokines, which exert pleiotropic effects on
important cell functions, including cell proliferation and
modulation of the immune system [72,73]. The IFN
system also mediates the first line of cellular anti-viral
response. Interestingly, about 70-75% of the cancer cells
are defective in the IFN pathway [74]. Mutation in B18R
gene allows the vaccinia virus to selectively infect (can-
cer) cells with defects in their IFN responses but not
normal cells with intact IFN responses. In this context,
canine cancer cells with defects of the IFN system may
be optimal targets for OVs, which exploit such defects
to support their own replication.
Numerous other strategies such as transductional tar-
geting, which use conditionally replicating viruses e.g.
canine adenovirus [30] and transcriptional targeting,
which includes use of specific promoters [29], may also
aid in selective targeting of oncolytic viruses to cancer
cells.
3.2 Spread of oncolytic viruses throughout the tumor
mass
Another challenge for effective oncolytic virotherapy is
the relatively poor penetration of the virus throughout
solid tumor masses. As observed in human cancers, the
slow spread of virus in solid tumors can be limiting and
determines the outcome of therapy [75]. The slow viral
spread within solid tumors might relate to the relatively
large size of OVs (e.g. around 200 nm of vaccinia virus
and around 90 nm for adenovirus). Recently, Altomonte
et al. showed that a single amino acid modification in
the fusion protein of NDV greatly improved the fuso-
genicity of a recombinant virus, thereby resulting in
enhanced tumor cell killing through the formation of
large multi-nucleated syncytia and spread of the virus
throughout the tumor mass [76].
The intratumoral spread and efficacy of OVs were also
improved by protease or hyaluronidase mediated diges-
tion of tumor extracellular matrix (ECM) [77-82]. Struc-
tural components of tumor ECM, such as collagens and
proteoglycans, have been shown to hinder distribution
of large therapeutic molecules and viruses [82]. There-
fore, the degradation of extracellular matrix with OV
expressing matrix proteases and collagenases may be a
useful strategy to achieve anticancer effects in both
humans and dogs.
3.3 Optimization of viral replication in immune-
competent hosts
Immune responses against viruses presumably limit
ongoing viral replication in immunocompetent dogs. In
this context, a high level of pre-existing immunity to
parental viruses in canine populations might limit the
use of oncolytic viruses for cancer therapy. The role of
virus-neutralizing antibodies following intravenous
administration remains to be determined. Use of unre-
lated viruses from different hosts, such as vaccinia for
dog cancers, may solve the problem of pre-existing
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immunity. However, carrier cell based therapy also pro-
vided promising results to escape pre-existing immunity
[83]. In this regard, several types of cells, such as
immune cells [84-86], stem cells [84,87,88] and tumor
cells [89,90] were successfully utilized as carriers of
oncolytic viruses to tumors. Specific delivery to tumors
and escape of the pre-existing antiviral immunity
increased the effective local viral dose in the tumor tis-
sue and thus enhanced the oncolytic effects [90-92].
However, mechanisms for the specific homing of carrier
cells to tumors are currently unknown.
In a recent study, canine osteosarcoma cells treated
with replication selective canine adenovirus (OCCAV)
were used as carrier vehicles for evading pre-existing
neutralizing antibodies against adenovirus. Systemic
antitumoral activity of OCCAV, even in presence of
adenovirus neutralizing antibodies, suggests a promising
approach to evade pre-existing immunity against the
viral vector [93].
The efficiency of OV replication in tumor bearing
immunocompetent dogs may be enhanced by various
means such as combination of viro- with chemo- [94]
or radiation therapy [95] or the conjunctive use of dif-
ferent oncolytic viruses [96].
3.4 Enhancing Anti-tumor Immunity and/or Anti-tumor
Effects of OVs by Virus-integrated Genes
Several strategies have been developed to achieve better
anti-tumoral immunity and/or anti-tumor effects after
OV cancer treatment. One strategy involves the integra-
tion of genes encoding either proteins with immunomo-
dulatory functions, such as cytokines or chemokines, or
tumor associated antigens (TAA). However, the optimal
balance between anti-viral and anti-tumor immune
responses is crucial for the success of these cancer
therapies in immunocompetent patients.
Another strategy to enhance the OV mediated anti-
cancer activity is targeting the tumor microenvironment
with replicating OVs. One promising target here is the
tumor neoangiogenesis. Recently, Breitbach and colleges
demonstrated that VSV directly infects and destroys
tumor vasculature in vivo, leaving the normal vascula-
ture intact [97]. In addition, armed oncolytic viruses can
also prevent neoangiogenesis, leading to cancer cell
necrosis. Vascular endothelial growth factor (VEGF) is a
protein that plays a key role in tumor angiogenesis [98].
Vaccinia virus encoding anti-VEGFR-1 protein decreases
neoangiogenesis at the tumor site and inhibits the
tumor growth [99]. Furthermore, blocking VEGF has
shown enhanced antitumor activity in a human xeno-
graft model where vaccinia virus was armed with anti-
VEGF antibody [100]. As seen for human tumors, signif-
icant expression of VEGF enhanced angiogenesis in
canine mammary gland tumors [101]. Also, increased
levels of VEGF-2 were observed in canine intracranial
meningiomas [102], mammary adenocarcinoma [103],
mastocytoma [104], mast cell tumors [105], and soft tis-
sue sarcoma [106]. Expression of VEGF in a variety of
canine cancers proves its role in canine tumor angiogen-
esis. Thus, oncolytic viruses armed with anti-VEGF
agents will be a possible therapeutic approach for canine
cancers.
Finally, the anticancer activity of OVs may also be
improved by expression of prodrug-converting enzymes
capable of producing a toxic product within tumor tis-
sue. Recombinant oncolytic viruses have been used to
express suicide genes that convert a pro-drug into toxic
drug within the tumor. Nitro-reductase enzyme from E.
coli causes reduction of inactive prodrug CB1954 to pro-
mote cell killing in feline cancer cells [107]. Similarly, 5-
Fluorouracil is a pyrimidine analog widely used in
canine cancer chemotherapy. Bacterial and/or yeast
cytosine deaminase (CDase) is a well characterized
enzyme-prodrug system that converts 5-Fluorocytosine
to 5-Fluorouracil which further leads to cell cycle arrest
and apoptosis leading to improved antitumor effects
[108]. Therefore, OVs armed with nitroreductase or
cytosine deaminase gene in combination with prodrugs
may synergistically destroy canine cancer cells.
4. Combination of Oncolytic Viruses with
Conventional Cancer Therapy in Dogs
One way to augment the efficacy of viral oncolysis is to
combine genetically engineered replication competent
viruses with standard anti-cancer therapies such as
chemo- and radiotherapy.
Several pre-clinical and clinical studies have shown
that combination of oncolytic viruses and radiation ther-
apy may achieve additional or synergistic anti-tumor
effects in in vitro and in vivo studies [109]. The experi-
mental data demonstrated that ionizing radiation may
also enhance viral replication and oncolysis within irra-
diated tumors.
Recently, the combination of oncolytic virotherapy
with chemotherapy has shown that use of these two
therapies with very distinct anti-tumor mechanisms may
also lead to synergistic interactions [110]. Therefore,
combination with radiation or chemotherapy may be a
key to the optimization of the oncolytic viral therapy in
dogs.
5. Ideal Oncolytic Virus for Canine Cancer
Therapy
Improvement of replicating viral systems for canine can-
cer treatment is continuously being achieved, and many
viruses are potentially useful for targeting canine cancer
cells. However, an important question that still raises
controversy is “which virus is best"? Several
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characteristics of oncolytic viruses for human cancer
treatment have been described earlier [111,112]. There
are no major variations as far as characteristics of ideal
oncolytic viruses for canine cancer. An ideal oncolytic
virus should demonstrate the following characteristics:
1. Efficient, safe and complete destruction of tumor
tissue.
2. Selective replication in canine cancer cells.
3. Resistance against pre-existing immunity in canine
populations.
4. Eliciting strong immune responses against tumor
cells.
5. Propagation-deficient (safe) in immunocompro-
mised patients.
6. Efficient clearance from the body preventing
latent or recurrent infection.
7. No integration of viral genome into the canine
genome.
8. Easily engineered to express antitumor agents.
9. Large recombinant gene carrying capacity.
10. Cost effectiveness and economy for widespread
use in canine cancer patients.
11. Easy to monitor with respect to successful tumor
colonization.
Many promising oncolytic viruses are being developed
with convincing results in preclinical trials. However, it
is unlikely that a virus will possess all the criteria of an
‘ideal’ oncolytic virus. In our opinion, vaccinia virus and
adenovirus strains exhibit several characteristics of an
ideal OV and show the most promising results in precli-
nical studies. In summary, similar to human cancer
patients, OVs seem to hold promise in treatment of
canine cancer.
6. Translation of Oncolytic Virotherapy from Dogs
to Humans and the Reverse
Canine cancers share many features in common with
human cancers including histological appearance, tumor
genetics, molecular targets and response to conventional
therapy [113-116]. In both species, tumor initiation and
progression is influenced by similar factors like age,
nutrition, sex and environmental exposure [117,118].
Dogs show as diverse cancers as seen in humans. These
similarities are further seen in the development of thera-
peutics. Furthermore, carcinogenesis and tumor biologic
behaviour in dogs have more features in common with
humans than with laboratory rodents [119]. Despite evi-
dence of oncolytic virus efficacy in mouse models of
cancers, many viruses fail in human trials due to unac-
ceptable toxicity or lack of efficacy [120]. Some strains
of oncolytic viruses such as human adenovirus and vac-
cinia virus in general do not productively replicate in
mouse cells. Thus, certain permissive cancer cells are
grown in immunocompetent animals to study virus
replication [121,122]. However, artificial establishment
of these tumors as subcutaneous xenografts raises con-
cern as to how well this model mimics their natural
human counterparts. Hence, pet dogs with tumors are
necessary models to demonstrate efficacy of OVs for
human cancers. An alternative approach may be the use
of species specific viruses in their natural host system.
For example, application of Canine Adenovirus 2 in
osteosarcoma of dog has shown to address the issue of
tumor setting, efficient virus replication and oncolysis
[30]. In this case, canine osteosarcoma resembles human
osteaosarcoma at several levels including histopathology
and metastatic behaviour [123]. However, Canine Ade-
novirus 2 shares similarities with human adenoviruses
which are used as oncolytic agents for human osteosar-
coma. The data from these studies are more reliable and
may be helpful in designing human clinical trials. How-
ever, as far as veterinary medicine is concerned, devel-
opment of oncolytic virotherapy for cancer to heal
canine patients is of prime importance. Many of the
treatment options used in veterinary medicine resemble
protocols used to treat human cancer patients. In addi-
tion, public release of nearly 99% canine genome
sequences provided a window of opportunity to expand
the scope of comparative oncology. Comparison of
canine genome sequences with the human genome sug-
gests that around 19000 genes identified in the dog
match to similar or orthologous genes in the human
genome [124]. Taking into consideration the value of
comparative oncology, data obtained from human clini-
cal trials can be effectively transferred to canines.
7. Conclusions
Canine tumors are complex entities that continue to
challenge modern veterinary medicine to develop more
reliable cancer therapies. The field of oncolytic virother-
apy is expanding and viruses continue to hold promise
as an effective therapeutic approach for human cancers.
Like in humans, oncolytic viruses replicate at the target
site and spread within tumors to lyse neoplastic cells
leading to decreased tumor burden in dogs. However
studies of oncolytic viruses for canine cancer treatment
are limited. It is not clear from past studies or from cur-
rent understandings of potential oncolytic viruses which
virus will be ‘best’ for canine cancer treatment. None-
theless, preclinical studies with vaccinia and adenovirus
for canine cancer therapy provided significant results
which need exploration in canine clinical trials. Simi-
larly, the therapeutic transgene expression capacity of
these viruses will likely also need to be developed.
Armed therapeutic viruses or genetically engineered
viruses represent a very appealing tumor targeting
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approach and a novel opportunity to generate agents
that could potentially cure canine cancers. Furthermore,
studying dogs with cancer is likely to provide valuable
information that is distinct from that generated in stu-
dies of rodent cancers alone. The importance of this
opportunity must therefore be considered for the devel-
opment of effective oncolytic therapy for canine as well
as human cancers patients. It is hoped that collective
efforts will contribute to the development of effective
and safe viruses for both human and canine cancer
therapy.
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